Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Targeting specific molecular alterations in glioblastoma (GBM) might more effectively kill tumor cells and increase survival. Vandetanib inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor 2. Sirolimus inhibits mammalian target of rapamycin (mTOR), a member the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurooncol
Autors principals: Chheda, Milan G., Wen, Patrick Y., Hochberg, Fred H., Chi, Andrew S., Drappatz, Jan, Eichler, April F., Yang, Daniel, Beroukhim, Rameen, Norden, Andrew D., Gerstner, Elizabeth R., Betensky, Rebecca A., Batchelor, Tracy T.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324090/
https://ncbi.nlm.nih.gov/pubmed/25503302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1680-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars